Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants.

VKA treatment reduces overall mortality by 26 % relative to placebo [ 14 ], and it is notable that all NOACs tested in phase III trials also demonstrated a strong trend towards reduced all-cause mortality in the ITT population compared with warfarin; this was statistically significant only for apixaban versus warfarin (HR, 0.89; p = 0.047) [ 23 ] and was close to statistical significance for the 150 mg bid dose of dabigatran (relative risk, 0.88; p = 0.051) [ 21 ].

also in 5,725 other papers